{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:16:44Z","timestamp":1718669804841},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00520-024-08551-x","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:01:35Z","timestamp":1715806895000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Alexander S.","family":"Bang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan T.","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Hirner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvina","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janellen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernice Y.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"8551_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","volume":"5","author":"LM Guggina","year":"2017","unstructured":"Guggina LM, Choi AW, Choi JN (2017) EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol Ther 5:135\u2013148. https:\/\/doi.org\/10.1007\/s40487-017-0050-6","journal-title":"Oncol Ther"},{"issue":"10","key":"8551_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803\u2013812. https:\/\/doi.org\/10.1038\/nrc1970","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"8551_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jaad.2022.01.051","volume":"88","author":"RF Wang","year":"2023","unstructured":"Wang RF, Ko D, Friedman BJ, Lim HW, Mohammad TF (2023) Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders. J Am Acad Dermatol 88(2):271\u2013288. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.051","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8551_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdcr.2019.11.008","volume":"6","author":"P Lertpichitkul","year":"2020","unstructured":"Lertpichitkul P, Wititsuwannakul J, Asawanonda P, Rerknimitr P (2020) Osimertinib-associated ashy dermatosis-like hyperpigmentation. JAAD Case Rep. 6(2):86\u201388. https:\/\/doi.org\/10.1016\/j.jdcr.2019.11.008. (Published 2020 Jan 17>)","journal-title":"JAAD Case Rep."},{"issue":"9","key":"8551_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/1759-7714.14383","volume":"13","author":"K Funai","year":"2022","unstructured":"Funai K (2022) Rare ashy dermatosis-like hyperpigmentation associated with osimertinib. Thorac Cancer 13(9):1436\u20131437. https:\/\/doi.org\/10.1111\/1759-7714.14383","journal-title":"Thorac Cancer"},{"issue":"7","key":"8551_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1080\/0284186X.2022.2082258","volume":"61","author":"A Muskat","year":"2022","unstructured":"Muskat A, Hoffman L, Kost Y, Mattis DM, Amin B, McLellan BN (2022) A rare case of erythema dyschromicum perstans arising in the setting of a third-generation tyrosine kinase inhibitor. Acta Oncol 61(7):830\u2013832. https:\/\/doi.org\/10.1080\/0284186X.2022.2082258","journal-title":"Acta Oncol"},{"issue":"6","key":"8551_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/bjd.19396","volume":"183","author":"KJ Ransohoff","year":"2020","unstructured":"Ransohoff KJ, Pugliese SB, Zaba LC, Rieger KE, Kwong BY (2020) Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series. Br J Dermatol 183(6):1130\u20131132. https:\/\/doi.org\/10.1111\/bjd.19396","journal-title":"Br J Dermatol"},{"key":"8551_CR8","doi-asserted-by":"publisher","unstructured":"Chuenwipasakul D, Wititsuwannakul J, Asawanonda P, Rerknimitr P (2021) Gefitinib-associated lichen planus pigmentosus-like eruption. Dermatol Online J 27(5). https:\/\/doi.org\/10.5070\/D327553616","DOI":"10.5070\/D327553616"},{"issue":"9","key":"8551_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam SS, Yang JC, Lee CK et al (2018) Osimertinib as first-line treatment of egfr mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36(9):841\u2013849. https:\/\/doi.org\/10.1200\/JCO.2017.74.7576","journal-title":"J Clin Oncol"},{"issue":"3","key":"8551_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.36849\/JDD.7156","volume":"22","author":"D Srinivasan","year":"2023","unstructured":"Srinivasan D, Gottlieb A (2023) Successful management of erythema dyschromicum perstans following topical ruxolitinib therapy. J Drugs Dermatol. 22(3):297\u2013299. https:\/\/doi.org\/10.36849\/JDD.7156","journal-title":"J Drugs Dermatol."},{"issue":"5","key":"8551_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/sj.jid.5700125","volume":"126","author":"V Alexeev","year":"2006","unstructured":"Alexeev V, Yoon K (2006) Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126(5):1102\u20131110. https:\/\/doi.org\/10.1038\/sj.jid.5700125","journal-title":"J Invest Dermatol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08551-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T12:08:11Z","timestamp":1718626091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08551-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["8551"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08551-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Stanford University IRB, approval #61215, and was conducted in accordance with the Declaration of Helsinki. Patients in this manuscript with identifying information have given written informed consent to publication of their case details.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}